TB-500 (Thymosin Beta-4 Fragment) During Pregnancy and Lactation: What the Evidence Shows

Why No FDA Pregnancy Rating Exists for TB-500

TB-500 is dispensed exclusively through 503A and 503B compounding pharmacies. Because it has never undergone a New Drug Application (NDA) review, the FDA has not assigned it a pregnancy category under the legacy A/B/C/D/X system or evaluated it under the newer Pregnancy and Lactation Labeling Rule (PLLR). That regulatory gap means prescribers have no standardized risk summary, no animal reproduction study summaries formatted per FDA guidance, and no lactation subsection to reference.

What the Regulatory Gap Means in Practice

The absence of a rating does not imply safety. It means the compound has simply never been evaluated through formal channels. For any drug lacking reproductive toxicology data, the American College of Obstetricians and Gynecologists (ACOG) advises clinicians to weigh theoretical risk against clinical necessity, a calculus that almost always favors discontinuation when the indication is elective tissue repair.

Compounding Pharmacy Oversight Limits

Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act produce TB-500 for individual prescriptions. These facilities are not required to submit reproductive safety data to the FDA. Batch-to-batch variability in peptide purity and potency introduces an additional layer of uncertainty for any patient population, but especially for pregnant individuals where dose precision matters most.

How TB-500 Works and Why That Matters for Pregnancy

TB-500 is a synthetic version of the 17-amino-acid active region (Ac-SDKP through the actin-binding domain) of thymosin beta-4 (Tβ4), a 43-amino-acid peptide found in nearly every human cell. The full-length Tβ4 protein sequesters monomeric G-actin, regulating cytoskeletal dynamics that drive cell migration, angiogenesis, and wound healing 1.

Actin Regulation and Cell Migration

TB-500 promotes cell migration by preventing premature actin polymerization. Cells that need to move (endothelial progenitors, inflammatory cells, keratinocytes) rely on this mechanism to reorganize their internal scaffolding. During embryonic development, these same actin-dependent migration pathways guide neural crest cells, cardiac progenitors, and vascular precursors to their correct anatomical positions. Exogenous TB-500 could theoretically amplify or disrupt these tightly choreographed migration events.

Angiogenesis: Benefit in Adults, Concern in Embryos

In adult tissues, TB-500-driven angiogenesis aids recovery from muscle tears, tendon injuries, and potentially cardiac ischemia. Goldstein et al. Documented that thymosin beta-4 promoted coronary vessel growth and improved cardiac function in post-myocardial-infarction animal models 1. The same pro-angiogenic action in a developing embryo could alter normal vascular patterning. Placental vasculogenesis, which begins during the third week of gestation and continues throughout pregnancy, is particularly sensitive to molecules that modulate endothelial cell behavior.

Anti-Inflammatory Signaling

TB-500 downregulates several inflammatory mediators, including NF-κB pathway components. While reducing inflammation benefits tissue repair in adults, the maternal immune system during pregnancy undergoes carefully staged inflammatory shifts. The first trimester requires a pro-inflammatory environment for implantation, the second trimester shifts toward anti-inflammatory tolerance, and the third trimester returns to pro-inflammatory signaling to initiate labor. Introducing an exogenous anti-inflammatory peptide could interfere with these transitions, though no study has tested this directly.

Animal Data on Thymosin Beta-4 in Development

No formal reproductive toxicology studies (ICH S5(R3) compliant) have been conducted on TB-500 or full-length thymosin beta-4. The available animal data come from developmental biology experiments designed to understand Tβ4 function, not to assess drug safety.

Cardiac Development Models

Tβ4 knockout and knockdown studies in zebrafish and mouse embryos demonstrate that thymosin beta-4 is required for normal cardiac development. Mice lacking Tβ4 showed embryonic lethality in some genetic backgrounds, with defects in coronary vessel formation and epicardial cell migration 2. These findings confirm that Tβ4 is not a bystander molecule during development. It is a required signal.

The question for TB-500 safety is whether adding exogenous peptide on top of endogenous production could cause gain-of-function effects. Excess angiogenic signaling during embryogenesis has been linked to vascular malformations in other peptide systems, but this has not been studied for Tβ4 specifically.

Wound Healing Models During Gestation

A small number of studies examined Tβ4 administration in pregnant rodents to evaluate fetal wound healing capacity. These experiments were not designed as safety studies and did not report systematic teratogenicity endpoints such as skeletal malformations, organ weights, or litter sizes in the format required by regulatory agencies 3.

What the Animal Data Cannot Tell Us

Animal developmental biology studies use Tβ4 concentrations, routes, and timing that differ from clinical TB-500 dosing (typically 2.0 to 2.5 mg subcutaneously, once or twice weekly). Zebrafish models involve gene knockouts rather than peptide supplementation. Mouse cardiac studies used direct intracardiac injection. Extrapolating from these models to a pregnant human receiving subcutaneous TB-500 requires assumptions that no current data can validate.

Lactation: Can TB-500 Transfer Into Breast Milk?

No study has measured TB-500 or thymosin beta-4 concentrations in human breast milk after exogenous administration.

Molecular Characteristics Relevant to Milk Transfer

Several pharmacokinetic properties influence whether a drug enters breast milk. TB-500's active fragment has a molecular weight of approximately 1,000 to 1,500 Da (the 17-amino-acid sequence), while full-length Tβ4 is roughly 4,963 Da. Peptides below 1,000 Da generally cross biological membranes more readily. TB-500 is water-soluble and does not bind extensively to plasma proteins in the conventional sense (its primary binding partner is intracellular G-actin). These characteristics suggest that some degree of milk transfer is plausible, though the peptide would likely undergo proteolytic degradation in the infant's gastrointestinal tract before systemic absorption.

Endogenous Tβ4 in Breast Milk

Thymosin beta-4 has been identified in human colostrum and mature breast milk as part of the natural peptidome 4. This endogenous presence complicates risk assessment: the infant's GI tract already encounters Tβ4 through normal breastfeeding. Whether exogenous TB-500 administration would raise milk Tβ4 levels above physiologic baseline is unknown.

The LactMed Standard

The National Library of Medicine's LactMed database does not contain an entry for TB-500 or thymosin beta-4. For drugs without LactMed data, the American Academy of Pediatrics recommends that clinicians consider the drug's necessity, the availability of safer alternatives, and the infant's age and health status. Since TB-500 is used for elective tissue repair, not life-threatening conditions, the risk-benefit analysis during lactation does not favor continued use.

Fertility Considerations Before Conception

Couples planning pregnancy should consider TB-500's potential effects on both male and female reproductive physiology, even though direct evidence is limited.

Female Fertility

Thymosin beta-4 is expressed in ovarian tissue and has been detected in follicular fluid 5. Its role in ovarian function remains poorly defined. Actin remodeling is critical during oocyte maturation and early embryonic cleavage divisions. Whether exogenous TB-500 at clinical doses affects these processes is unstudied.

Male Fertility

No published data address TB-500's effects on spermatogenesis, sperm motility, or sperm morphology. Tβ4 is present in seminal fluid, and its actin-sequestering function may play a role in sperm capacitation, but this has not been investigated in the context of exogenous peptide supplementation.

Recommended Washout Period

Given the absence of formal pharmacokinetic studies, a conservative approach is to discontinue TB-500 at least two to four weeks before attempting conception. Peptide hormones and fragments typically have short plasma half-lives (minutes to hours), but the downstream biological effects on tissue remodeling may persist longer. Dr. Allan Goldstein, who pioneered thymosin research at George Washington University, noted that "thymosin beta-4's effects on cell migration and angiogenesis extend well beyond the peptide's presence in circulation" 1. A two-week minimum washout allows residual tissue-level effects to subside.

Clinical Guidance for Prescribers

The Endocrine Society and ACOG have not issued specific guidance on TB-500 use during pregnancy or lactation. Prescribers must rely on general principles for unrated compounds.

Decision Framework

Three questions should guide the clinical conversation. First, is the indication urgent? TB-500 is used for musculoskeletal repair and recovery, conditions that are rarely time-sensitive enough to justify gestational exposure. Second, are there safer alternatives? Physical therapy, controlled loading protocols, and platelet-rich plasma (PRP) offer tissue-repair support with more established safety profiles during pregnancy. Third, what is the patient's gestational timing? First-trimester exposure carries the highest theoretical risk because organogenesis is most active during weeks 3 through 8.

Documentation Recommendations

The American Society for Reproductive Medicine (ASRM) recommends that clinicians document informed consent discussions when prescribing any compound lacking reproductive safety data to patients of childbearing potential. This documentation should specify that no human pregnancy data exist, that animal data are insufficient for risk classification, and that the patient has been advised to use effective contraception during treatment.

Monitoring if Inadvertent Exposure Occurs

If a patient discovers pregnancy while using TB-500, the prescriber should discontinue the peptide immediately and refer for standard first-trimester screening. No TB-500-specific monitoring protocols exist. Standard anatomical ultrasound at 18 to 20 weeks and routine prenatal labs remain the appropriate surveillance tools. The patient should be counseled that inadvertent early exposure to a short-acting peptide, while not ideal, does not automatically predict adverse outcomes. As ACOG Committee Opinion No. 723 states, "a patient's anxiety about an exposure should not drive unnecessary testing or termination recommendations in the absence of known teratogenic risk" 6.

What We Still Do Not Know

The evidence gaps around TB-500 and pregnancy are substantial. No human case reports, no formal animal reproductive toxicology (NOAEL determination, teratogenicity screening, peri/postnatal development studies), no milk transfer pharmacokinetics, and no fertility impact data exist. Filling these gaps would require investment that compounding pharmacies have no regulatory obligation or financial incentive to undertake.

Until those studies are conducted, the only evidence-based recommendation is avoidance. Patients who have used TB-500 and subsequently become pregnant can be reassured that the peptide's short half-life and the body's own endogenous Tβ4 production make catastrophic risk unlikely, but "unlikely" is not the same as "studied." The standard of care for compounds without reproductive data remains discontinuation before conception and throughout lactation, full stop.